Biricodar
From Wikipedia, the free encyclopedia
 |
This article is orphaned as few or no other articles link to it. Please help introduce links in articles on related topics. (October 2006) |
- "Incel" redirects here. The term is also sometimes used to refer to involuntary celibacy.
 |
|
|
Biricodar
|
|
| Systematic (IUPAC) name | |
| 1,7-di(pyridin-3-yl)heptan-4-yl (2S)-1-[2-oxo-2-(3,4,5-trimethoxyphenyl)acetyl] piperidine-2-carboxylate |
|
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C34H41N3O7 |
| Mol. mass | 603.705 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Biricodar (INN, codename VX-170, marketed as the dicitrate salt under the trade name Incel) is a pharmaceutical drug released by Vertex Pharmaceuticals in 1999 to help treat ovarian cancer patients.
[edit] External links
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
